- Contract rate Transactions with the intermediate parent company 3 (Unit: Thousand Baht) For the three-month periods ended 31 March Consolidated financial statements Separate financial statements Transfer

(THIS REPORT DISCUSSES PRINCIPAL CHANGES ON THE UNREVIEWED CONSOLIDATED FINANCIAL STATEMENT) LH FINANCIAL GROUP PUBLIC COMPANY LIMITED MANAGEMENT DISCUSSION AND ANALYSIS FOR THE FIRST QUARTER ENDED

(THIS REPORT DISCUSSES PRINCIPAL CHANGES ON THE REVIEWED CONSOLIDATED FINANCIAL STATEMENT) LH FINANCIAL GROUP PUBLIC COMPANY LIMITED MANAGEMENT DISCUSSION AND ANALYSIS FOR THE FIRST QUARTER ENDED 31

) Total comprehensive loss for the period (63.67) (61.60) (2.07) 3.36 Non-controlling interests (4.30) (3.39) (0.91) 26.68 Equity holders of the Company (59.26) (57.72) (1.54) 2.67 Basic loss per share

comprehensive loss for the period (63.67) (61.60) (2.07) 3.36 Non-controlling interests (4.30) (3.39) (0.91) 26.68 Equity holders of the Company (59.26) (57.72) (1.54) 2.67 Basic loss per share (0.08) (0.08

purchase agreement and/or relevant agreements and complete the transfer of BS Myco Biotech shares on June 12, 2019. This Acquisition is considered as the assets acquisition transaction of listed company and

the company to rectify its financial condition to comply with the net fund maintenance rules as well as solve the issue of its improper and inadequate management and personnel structures and the case

of Thailand Enclosure : 1. Financial Statements for the Second quarter ended June 30,2019 2. Management Discussion and Analysis Nawarat Patanakarn Public Company Limited would like to submit Reviewed

accept the transfer of the second portion from the Seller. In this case, the Company is entitled to sell the first portion to the Seller and/or a person designated by the Seller at a price that the Company

Assets of Wattanapat Hospital Trang Public Company Limited As Wattanapat Hospital Trang Public Company Limited (“the Company”) had approved the resolution of its Board of Director’s Meeting No.4/2019 held